These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8618474)

  • 21. High-dose cytosine arabinoside remission induction for acute myelogenous leukemia: comparison of two regimens of remission maintenance.
    Curtis JE; Messner HA; Minden MD; Lipton JH; Lockwood GA; Tritchler DL; McCulloch EA
    Leukemia; 1992 Nov; 6(11):1192-8. PubMed ID: 1434804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
    He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
    Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose chemotherapy in adult acute myeloid leukemia: rationale and results.
    Stasi R; Venditti A; Del Poeta G; Aronica G; Abruzzese E; Pisani F; Cecconi M; Masi M; Amadori S
    Leuk Res; 1996 Jul; 20(7):535-49. PubMed ID: 8795687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
    Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
    Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
    Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome.
    Larson RA
    Leukemia; 1996 Apr; 10 Suppl 1():S23-5. PubMed ID: 8618465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
    Raza A; Gezer S; Anderson J; Lykins J; Bennett J; Browman G; Goldberg J; Larson R; Vogler R; Preisler HD
    Exp Hematol; 1992 Nov; 20(10):1194-200. PubMed ID: 1426099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose ara-C in older adults with acute leukemia.
    Herzig RH
    Leukemia; 1996 Apr; 10 Suppl 1():S10-1. PubMed ID: 8618461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
    Cassileth PA; Andersen JW; Bennett JM; Harrington DP; Hines JD; Lazarus HM; Mazza JJ; McGlave PP; O'Connell MJ; Paietta E
    Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
    Castagnola C; Nozza A; Corso A; Bernasconi C
    Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
    Anderlini P; Luna M; Kantarjian HM; O'Brien S; Pierce S; Keating MJ; Estey EH
    Leukemia; 1996 Apr; 10(4):600-8. PubMed ID: 8618434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
    Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
    Visani G; Tosi P; Zinzani PL; Manfroi S; Ottaviani E; Testoni N; Clavio M; Cenacchi A; Gamberi B; Carrara P
    Leukemia; 1994 Nov; 8(11):1842-6. PubMed ID: 7526088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.